Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
about
Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responsesIntegrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early TreatmentHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactAntiretroviral therapy: Shifting sandsEffectiveness and safety of oral HIV preexposure prophylaxis for all populationsClinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in DeliveryTransmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DCLow Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementationPreexposure prophylaxis-selected drug resistance decays rapidly after drug cessationSafety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.Performance of Determine Combo and other point-of-care HIV tests among Seattle MSM.Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports.Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States.Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis.Safer Conception Strategies for HIV-Serodiscordant Couples: How Safe Is Safe Enough?Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection.The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.Awareness and Acceptance of HIV Pre-exposure Prophylaxis among Medical Personnel and Men Who Have Sex with Men in Korea.Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire.An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides.Within-patient mutation frequencies reveal fitness costs of CpG dinucleotides and drastic amino acid changes in HIV.p24 revisited: a landscape review of antigen detection for early HIV diagnosis
P2860
Q26774878-CB77A605-2048-4B68-8C4F-3457DF634AB2Q26778085-950D30FD-2027-44F5-A532-8D11FB7E279DQ28552455-19D33AF2-0F0C-4B1B-9FC2-857763CD45A8Q30384683-83242760-E328-4FD9-A9BA-586F09D56343Q34677217-7AF2A5C8-8AC0-4B17-B275-782F9CD245B3Q35541521-0377F5D0-4D1B-4872-BD0D-A89EABDC91FCQ36053733-2C5A57D0-AA29-423F-9DFC-E6BC6C1601A3Q36290753-634C9342-98EB-4B95-9065-34E2A54BBF17Q36296707-A7D30747-22A0-4D99-8AE4-6EA0D66C8A76Q36438778-117F4540-067E-435F-A8CC-519E3F2DBD79Q36586078-0407398A-AE7A-4D86-97D7-60642D4EFCE9Q36604715-8DCB33A4-D643-44DA-86DB-9D65EEB870B4Q36739989-D225C024-665E-4C5C-B94D-B803A3E6B79AQ37146567-41418479-0B7C-405B-9645-17B93D4B09D9Q38644317-326CA949-2637-49AE-99C1-743CE8F7A7A1Q38849706-AC7F613A-C31D-4607-9476-56B41CEFB5BCQ39520219-DF0263D3-4F47-4B51-9764-6E795B571EBEQ39825094-D69B6883-0EB6-4380-A8C1-740777AC2300Q40173474-496A42B1-DFCF-4756-B275-8B5CD0344260Q40464768-FA0738DC-9944-437E-88F9-9FCC983FD734Q43201094-C86252C2-3D95-4623-A6D0-58739B45C968Q43201412-1F57A247-5AA7-4309-8654-226A6649F9E3Q47398084-44DD608B-1B3F-49FE-9EFE-4838FDACCEF0Q52567034-B6FB8768-4AFC-4D8E-9576-A62F27A3BB15Q52654663-B35A262A-5DE4-47D9-A1AF-319902FA1B06Q52718554-F25CABC5-E1FC-414E-9616-343B01FD8040Q55340159-13E0453F-AEFC-44E2-BC28-D1135BB6F391Q55436855-58A16B7A-4BF2-44D3-B9C4-884C447F29AEQ55500682-E849B072-22C4-44A8-9F05-E43CF8C0E8A4Q57150995-15C4A5A4-25D6-4F36-A7EA-03F0F8EDDC33
P2860
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Risk of drug resistance among ...... agent preexposure prophylaxis.
@ast
Risk of drug resistance among ...... agent preexposure prophylaxis.
@en
type
label
Risk of drug resistance among ...... agent preexposure prophylaxis.
@ast
Risk of drug resistance among ...... agent preexposure prophylaxis.
@en
prefLabel
Risk of drug resistance among ...... agent preexposure prophylaxis.
@ast
Risk of drug resistance among ...... agent preexposure prophylaxis.
@en
P2093
P2860
P50
P356
P1476
Risk of drug resistance among ...... agent preexposure prophylaxis.
@en
P2093
Connor O McCoy
Craig W Hendrix
Dara A Lehman
Dylan Peterson
Frederick A Matsen
Gerald Mbara
Jared M Baeten
Julie F Weis
Katherine K Thomas
Lisa Frenkel
P2860
P304
P356
10.1093/INFDIS/JIU677
P407
P577
2015-01-13T00:00:00Z